


APR 05 2002

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



In re Application of

Marc J. MCKENNON, et al.

Serial No.: 09/859,503

Group Art Unit: 1624

Filed: May 18, 2001

Examiner: M. Berch

For: PYRIDOPYRIMIDINE COMPOUNDS AND THEIR USES

THE COMMISSIONER FOR PATENTS AND TRADEMARKS
Washington, DC 20231

Dear Sir:

Transmitted herewith is an Amendment in the above identified application.

☐
☐
☐

No additional fee is required.

Applicant is entitled to small entity status under 37 CFR 1.27

Also attached:

The fee has been calculated as shown below:

	NO. OF CLAIMS	HIGHEST PREVIOUSLY PAID FOR	EXTRA CLAIMS	RATE	FEE
Total Claims	36	36	0	\$18.00 =	\$0.00
Independent Claims	12	11	1	\$84.00 =	\$84.00
Multiple claims newly presented					\$0.00
Fee for extension of time					\$0.00
Total of Above Calculations					\$84.00

- ☒ Please charge my Deposit Account No. 500417 in the amount of \$84.00. An additional copy of this transmittal sheet is submitted herewith.
- ☒ The Commissioner is hereby authorized to charge payment of any fees associated with this communication or credit any overpayment, to Deposit Account No. 500417, including any filing fees under 37 CFR 1.16 for presentation of extra claims and any patent application processing fees under 37 CFR 1.17.

Respectfully submitted,

MCDERMOTT, WILL & EMERY

Cameron K. Weiffenbach

Registration No. 44,488

600 13th Street, N.W.
Washington, DC 20005-3096
(202)756-8000 CKW:apr
Facsimile: (202)756-8087
Date: April 2, 2002



Docket No.: 44033-122

TECH CENTER 1600/2900

APR 15 2002

RECEIVED

#6A
PS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Marc J. McKennon, et al.

Application No.: 09/859,503

Filed: May 18, 2001

For: PYRIDOPYRIMIDINE COMPOUNDS AND THEIR USES

:
:
:
:
:
:
:

Group Art Unit: 1624

Examiner: M. L. Berch

AMENDMENT and REQUEST FOR RECONSIDERATION
UNDER 37 CFR § 1.111

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

This is a response to the non-final Office Action dated January 2, 2002. Please amend the above-identified patent application as set forth below.

AMENDMENT

IN THE CLAIMS:

Please cancel claim 3 without prejudice or disclaimer thereof.

Please amend claims 1, 4, 6, 34 and 36 to read as follows:

1. A therapeutic compound, including resolved enantiomers, diastereomers, tautomers, salts and solvates thereof, having one of the following formulae:

04/03/2002 CNGUYEN 00000125 500417 09859503

01 FC:102

84.00 CH

Sub
B1